The innovative software "CAAS vFFR" by Pie Medical Imaging for the non-invasive physiological assessment of intermediate coronary lesions is the subject of FAST III, a multicenter European clinical trial which will investigate the effectiveness of the ve
Dec 9, 2021
MAASTRICHT, Netherlands, Dec. 9, 2021 /PRNewswire/ -- Pie Medical Imaging ("PMI"), a global leader in cardiac imaging, part of the Esaote Group, today announced the beginning of FASTIII, a multicenter randomized clinical trial which will investigate the use of angiography-based vessel fractional flow reserve (CAAS vFFR) in patients undergoing coronary revascularization procedures. CAAS vFFR for real-time in cathlab non-invasive calculation of lesion significance